Brookstone Capital Management Neurocrine Biosciences Inc Transaction History
Brookstone Capital Management
- $7.19 Billion
- Q3 2025
A detailed history of Brookstone Capital Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Brookstone Capital Management holds 4,353 shares of NBIX stock, worth $623,393. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,353Holding current value
$623,393% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
683Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.03 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$797 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$640 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$442 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...